Tnf Inhibitor-Associated Psoriasis
Median survival of first-line TNF inhibitor in ankylosing spondylitis nearly 11 years
Patients with ankylosing spondylitis starting their first TNF inhibitor, and who stayed on said treatment for at least 2 years, demonstrated a median drug survival period of 10.6 years, with 24% discontinuing, according to data.
Hospitalization, mortality risks in RA-ILD similar for TNF inhibitors, non-TNF agents
SAN DIEGO — TNF inhibitors demonstrate comparable risks for hospitalization and death vs. non-TNF agents in patients with rheumatoid arthritis-associated interstitial lung disease, according to data presented at ACR Convergence 2023.
Little evidence suggests clear superiority of any drug class in rheumatoid arthritis
Little evidence suggests that any specific biologic or targeted synthetic disease-modifying antirheumatic drug is superior to another for rheumatoid arthritis, highlighting the importance of individualized treatment, according to data.
Growing psoriatic arthritis armamentarium can target specific disease domains
DESTIN, Fla. — An ever-increasing array of treatment options is allowing rheumatologists to target specific disease domains in their patients with psoriatic arthritis, according to a speaker at the Congress of Clinical Rheumatology East.
JAK inhibitors have significant impact in psoriatic arthritis, but safety concerns remain
Despite some safety concerns, Janus kinase, or JAK, inhibitors, are carving out a place as important treatment options for a number of autoimmune diseases, including psoriatic arthritis.
Top in rheumatology: Fibromyalgia in US military, tapering TNF inhibitors
In the top story in rheumatology last week, new data showed that U.S. active-duty service members with PTSD had much higher rates of fibromyalgia compared with the overall population of service members who were awaiting deployment.
COSMOS: Guselkumab improves joint, skin symptoms in anti-TNF-refractory PsA
Guselkumab 100 mg administered every 8 weeks results in “significantly higher” ACR20 response rates vs. placebo in patients with psoriatic arthritis who had an inadequate response to TNF inhibitors, according to data presented at the EULAR 2021 Virtual Congress.
Despite abundance of biologics for PsA, disease domains 'dictate treatment'
Although a range of biologic options are available to clinicians treating psoriatic arthritis, it crucial to know which disease domains are involved as this will “dictate treatment,” according to a presenter at the Biologic Therapies Summit.
Exposure to TNF inhibitors increases psoriasis risk in children with IBD, JIA
Children with inflammatory bowel disease, juvenile idiopathic arthritis and chronic noninfectious osteomyelitis had an increased rate of psoriasis, and those exposed to tumor necrosis factor inhibitor therapy exhibited the highest risk, according to research presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.